Newsroom | 3904 results

GALWAY, Ireland--(BUSINESS WIRE)--Loci Orthopaedics Ltd, a clinical stage orthopaedic medical device company, is pleased to announce its participation at the prestigious Triennial Congress of the International Federation of Societies for Surgery of the Hand (IFSSH) and International Federation of Societies for Hand Therapy (IFSHT). Hosted by the American Society for Surgery of the Hand, American Society of Hand Therapists, and American Association for Hand Surgery, the event is taking place in...

KAWASAKI, Japan--(BUSINESS WIRE)--National Cancer Center and PeptiDream Inc.: Overview The National Cancer Center (President: Hitoshi Nakagama, hereinafter “NCC”) Hospital East (Director: Toshihiko Doi), The National Cancer Center Exploratory Oncology Research & Clinical Trial Center (Director: Katsuya Tsuchihara, “EPOC”) and PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (CEO: Patrick C. Reid, “PeptiDream”) (Tokyo: 4587) today announced promising results from the...

DUBLIN--(BUSINESS WIRE)--The "2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA" report has been added to ResearchAndMarkets.com's offering. This report provides a compilation and analysis of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2024. In addition, publicly available 2024 sales data of biosimilar antibodies and proteins as well as of new biologic modalities such as gene and cell th...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD). The study results did not demonstrate a meaningful difference in complete response (CR) or overal...

GENEVA--(BUSINESS WIRE)--Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease...

GENEVA--(BUSINESS WIRE)--Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2024, and provided a business update. “2024 was a transformational year for Precision BioSciences as we solidified ourselves as a leading in vivo gene editing company, and we...

BOSTON--(BUSINESS WIRE)--Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced its latest development in identifying the secretory dysfunction responsible for Alzheimer’s Disease along with advancements in therapeutic neuronal nanomachines. These innovations may transform the future of Alzheimer’s research and treatment approaches. The company’s new findings suggest that combining porosome restoration with small molecule and peptide therapy may not only slow the progression of Alz...

PLANO, Texas & BALTIMORE--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced dosing of the first patient in its Phase 1 clinical trial evaluating STM-01 as a treatment for heart failure with preserved ejection fraction (HFpEF). This is the first-ever clinical study of an allogeneic, off-the-shelf stem cell therapy in HFpEF, a leading cause of hospitalization, morbidity,...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases...